Triphenylphosphine Oxide

Triphenylphosphine Oxide

SCHEMBL15533922

O=P(c1ccccc1)(c1ccccc1)c1ccccc1.[Pd]

nearest known ligand 0.58

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA2 P00918 1/20 0.55
CA4 P22748 1/20 0.55
CA5A P35218 1/20 0.55
LMNA P02545 1/20 0.54
CFTR P13569 1/20 0.48
ALDH1A1 P00352 4/20 0.46
GAA P10253 2/20 0.46
L3MBTL1 Q9Y468 2/20 0.46
TDP1 Q9NUW8 1/20 0.46
MAPT P10636 1/20 0.46
ALPG P10696 1/20 0.46
ALOX12 P18054 1/20 0.46
NPY1R P25929 1/20 0.46
HTT P42858 1/20 0.46
NPY2R P49146 1/20 0.46
NPSR1 Q6W5P4 1/20 0.46
MEN1 O00255 2/20 0.45
KMT2A Q03164 2/20 0.45
ALOX15 P16050 1/20 0.44
TSHR P16473 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Triphenylphosphine Oxide SCHEMBL513223 0.97 CA2 (0.58) CA2CA4CA5ALMNACFTR
Triphenylphosphine Oxide SCHEMBL3949 0.97 CA2 (0.58) CA2CA4CA5ALMNACFTR
Triphenylphosphine Oxide SCHEMBL3753871 0.93 CA2 (0.55) CA2CA4CA5ALMNACFTR
Triphenylphosphine Oxide SCHEMBL8431251 0.93 CA2 (0.63) CA2CA4CA5ALMNACFTR
Triphenylphosphine Oxide SCHEMBL11214761 0.93 CA2 (0.55) CA2CA4CA5ALMNACFTR
Triphenylphosphine Oxide SCHEMBL9425396 0.93 CA2 (0.55) CA2CA4CA5ALMNACFTR
SCHEMBL5439069 0.93 LMNA (0.60) CA2CA4CA5ALMNACFTR
Triphenylphosphine Oxide SCHEMBL7991003 0.93 CA2 (0.55) CA2CA4CA5ALMNACFTR
SCHEMBL132983 0.93 LMNA (0.60) CA2CA4CA5ALMNACFTR
Triphenylphosphine Oxide SCHEMBL7551485 0.93 CA2 (0.55) CA2CA4CA5ALMNACFTR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 187 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117088852-B Preparation and palladium removal method of crizotinib intermediate 山东省科学院菏泽分院 2024-04-16 CN claimed
CN-117088852-A Preparation and palladium removal method of crizotinib intermediate 山东省科学院菏泽分院 2023-11-21 CN claimed
CN-106221280-A Novel organic dye sensitizer containing BODIPY conjugated units and preparation method thereof 东莞理工学院 2016-12-14 CN claimed
CN-103524486-B The beta-lactam compound that N-quinolyl replaces and pharmaceutical composition and synthetic method and application KUNMING INSTITUTE OF BOTANY, CHINESE ACADEMY OF SCIENCES (CN) 2016-03-02 CN claimed
CN-103524486-A N-quinolyl substituted beta-lactam compound, as well as pharmaceutical composition, synthetic method and application of compound KUNMING INST BOTANY CN ACAD 2014-01-22 CN claimed
CN-1314691-C Faropenem sodium preparation method LUNAN PHARM GROUP CORP (CN) 2007-05-09 CN claimed
CN-1255379-C E-alpha-chloro alkyllene-beta-lactan compound synthetic method and its use SHANGHAI INST ORGANIC CHEM (CN) 2006-05-10 CN claimed
CN-1733772-A Faropenem sodium preparation method LUNAN PHARM GROUP CORP (CN) 2006-02-15 CN claimed
CN-1616423-A E-alpha-chloro alkyllene-beta-lactan compound synthetic method and its use SHANGHAI INST ORGANIC CHEM (CN) 2005-05-18 CN claimed
CN-1523022-A Z-alpha-halogenated alkylidene-beta-lactone compound, synthesis method and use thereof 中国科学院上海有机化学研究所 2004-08-25 CN claimed
CN-117088852-B Preparation and palladium removal method of crizotinib intermediate 山东省科学院菏泽分院 2024-04-16 CN disclosed
CN-117088852-B Preparation and palladium removal method of crizotinib intermediate 山东省科学院菏泽分院 2024-04-16 CN disclosed
CN-117483004-A Palladium-containing composition and method for producing hydrogen peroxide 三菱瓦斯化学株式会社 2024-02-02 CN disclosed
US-11883809-B2 Palladium-containing composition and hydrogen peroxide production method MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) 2024-01-30 US disclosed
CN-117088852-A Preparation and palladium removal method of crizotinib intermediate 山东省科学院菏泽分院 2023-11-21 CN disclosed
CN-1216556-A Polymers with spiro atoms and their use as electroluminescent materials HOECHST AG (DE) 1999-05-12 CN disclosed
CN-1216539-A Heterocyclic azahexane derivatives with antiviral activity NOVARTIS AG (CH) 1999-05-12 CN disclosed
CN-1197452-A Azetidinone derivatives for treatment of atherosclerosis SMITHKLINE BEECHAM PLC (GB) 1998-10-28 CN disclosed
CN-1023399-C 8-Substituted-2-aminotetralines ASTRA AB (SE) 1994-01-05 CN disclosed
CN-1047494-A 2-amino-1,2,3,4-tetralin compounds that new 8-replaces ASTRA AB (SE) 1990-12-05 CN disclosed